Quarterly ResultAug 7, 2026, 07:37 AM
COGNITION THERAPEUTICS Q2 Net Loss $3.93M; Cash $34.01M
AI Summary
COGNITION THERAPEUTICS INC reported a net loss of $3.93 million for the second quarter of 2026, an improvement from a $6.73 million loss in the same period last year. For the first half of 2026, the net loss was $8.50 million, down from $15.21 million in the prior year. The company's cash and cash equivalents stood at $34.01 million as of June 30, 2026, and it believes these funds are sufficient to support operations for at least one year. The company also raised $6.95 million through its 2025 At-The-Market (ATM) program during the first six months of 2026.
Key Highlights
- Net loss for Q2 2026 was $3.93 million, compared to $6.73 million in Q2 2025.
- Net loss for H1 2026 was $8.50 million, compared to $15.21 million in H1 2025.
- Cash and cash equivalents were $34.01 million as of June 30, 2026, down from $36.81 million at Dec 31, 2025.
- Research and development costs decreased to $5.10 million in Q2 2026 from $11.48 million in Q2 2025.
- Grant income was $3.52 million in Q2 2026, down from $7.11 million in Q2 2025.
- Sold 5,506,610 shares under 2025 ATM for gross proceeds of $6.95 million in H1 2026.
- The Lincoln Park Purchase Agreement expired on March 10, 2026.
- Company believes current cash is sufficient to fund operations for one year from filing date.
Price Impact
More from CGTX